Q2 EPS Estimates for iTeos Therapeutics Reduced by Wedbush

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Stock analysts at Wedbush lowered their Q2 2025 earnings per share (EPS) estimates for iTeos Therapeutics in a research note issued to investors on Monday, April 28th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.85) for the quarter, down from their previous estimate of ($0.80). Wedbush currently has a “Outperform” rating and a $25.00 target price on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.49) per share. Wedbush also issued estimates for iTeos Therapeutics’ Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.88) EPS, FY2025 earnings at ($3.35) EPS, Q1 2026 earnings at ($0.98) EPS, Q2 2026 earnings at ($1.03) EPS, Q3 2026 earnings at ($1.08) EPS, Q4 2026 earnings at ($1.10) EPS, FY2026 earnings at ($4.19) EPS, FY2027 earnings at ($4.79) EPS, FY2028 earnings at ($4.55) EPS and FY2029 earnings at ($3.20) EPS.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings data on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.14.

Several other equities research analysts have also recently issued reports on the stock. Wells Fargo & Company decreased their price objective on shares of iTeos Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a report on Thursday, March 6th. Finally, JPMorgan Chase & Co. dropped their price objective on iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th.

iTeos Therapeutics Stock Up 3.6 %

Shares of iTeos Therapeutics stock opened at $7.77 on Thursday. iTeos Therapeutics has a 52-week low of $4.80 and a 52-week high of $18.75. The company has a market capitalization of $296.77 million, a P/E ratio of -2.47 and a beta of 1.43. The company has a 50 day moving average of $6.59 and a 200 day moving average of $7.54.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. CWM LLC lifted its position in iTeos Therapeutics by 428.7% in the first quarter. CWM LLC now owns 8,554 shares of the company’s stock valued at $51,000 after acquiring an additional 6,936 shares during the last quarter. Peapod Lane Capital LLC lifted its holdings in shares of iTeos Therapeutics by 24.6% in the 1st quarter. Peapod Lane Capital LLC now owns 135,655 shares of the company’s stock valued at $810,000 after purchasing an additional 26,802 shares during the last quarter. Exchange Traded Concepts LLC boosted its position in shares of iTeos Therapeutics by 25.1% in the 1st quarter. Exchange Traded Concepts LLC now owns 17,308 shares of the company’s stock valued at $103,000 after purchasing an additional 3,468 shares during the period. Wellington Management Group LLP grew its stake in iTeos Therapeutics by 4.3% during the 4th quarter. Wellington Management Group LLP now owns 110,332 shares of the company’s stock worth $847,000 after buying an additional 4,563 shares during the last quarter. Finally, Public Employees Retirement System of Ohio increased its position in iTeos Therapeutics by 192.2% during the fourth quarter. Public Employees Retirement System of Ohio now owns 84,220 shares of the company’s stock worth $647,000 after buying an additional 55,394 shares during the period. 97.16% of the stock is owned by hedge funds and other institutional investors.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.